After netting $200M, Synthego to break ground on its manufacturing facility
California-based biotech Synthego has been mainly focused on developing CRISPR-based tools to help researchers in academia and biotech, but its latest move now is turning its attention more towards manufacturing.
The company has broken ground on a 20,000-square-foot manufacturing facility in the San Francisco Bay Area, expanding its GMP capacity by 30 times, Synthego said in an email to Endpoints News. The facility is also going to manufacture materials for translational and clinical research development for cell and gene therapies as well.
According to the company, the factory is an expansion that will enable Synthego to significantly expand the production of its gene-editing tools and produce the elements necessary for CRISPR-mediated gene therapies throughout the industry.
The new facility is expected to be built and start operations within the year. According to the company, a significant amount of capacity has already been prioritized for its customers but it has not specified how many customers the company has.
While the company did not divulge the specifics on the cost of the facility when the company netted their $200 million Series E in February — some of those funds were dedicated to manufacturing, but no specifics were presented.
“We designed this facility to deliver our GMP single guide RNA (sgRNA) at a scale not only to meet the needs of our biopharma partners but to drive the industry forward and realize the full potential of the rapidly expanding field of cell and gene therapies,” said Synthego CEO Paul Dabrowski.
According to the company, the facility will contain 10,000 square feet of lab space, including dedicated quality control and research and development labs. 7,000 square feet will be a dedicated cleanroom space for 24/7 parallel batch production. This will allow customers to scale from early-phase research to process development to clinical research and development activities needed for FDA submissions.
Synthego has been growing rapidly over the past few years as the company netted a $100 million D round in 2020 to build out its platform of CRISPR assays, screens and engineered cell lines.
CRISPR-related manufacturing is also becoming more and more prevalent with Aldevron and Intellia inking deals to establish manufacturing sites or to make specific CRISPR materials.